Theratechnologies regains rights to EGRIFTA (tesamorelin for injection) in the United States

May 01, 2014
PDF Version
Supporting Materials:
Montreal, Canada – May 1, 2014 - Theratechnologies Inc. (TSX: TH) today announced the closing of the transaction with EMD Serono, Inc. in which Theratechnologies regained all rights to EGRIFTA® (tesamorelin for injection) in the United States, including its commercialisation rights.